AWM
TBPH icon

Avior Wealth Management’s Theravance Biopharma TBPH Stock Holding History

Avior Wealth Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-13
Closed -$116 – 3572
2024
Q1 		$116 Buy
+13
New +$120 ﹤0.01% 3128

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

Avior Wealth Management's TBPH Position: Q2 2024 in Review

Avior Wealth Management sold out of Theravance Biopharma (TBPH) in Q2 2024, closing a stake of 13 shares — an estimated $116 sold.

Avior Wealth Management first reported a position in TBPH in Q1 2024 and held it in 1 quarter. The position peaked at $116 in Q1 2024. 132 funds tracked by Wall St. Rank hold TBPH as of Q2 2024.

  • Avior Wealth Management reported no remaining Theravance Biopharma position as of Q2 2024 after selling out during the quarter.
  • Avior Wealth Management sold 13 Theravance Biopharma shares in Q2 2024, an estimated $116.
  • Avior Wealth Management first reported a position in Theravance Biopharma in Q1 2024 and held it in 1 quarter.
  • Avior Wealth Management's Theravance Biopharma position peaked at $116 in Q1 2024.
  • 132 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2024.

Based on Avior Wealth Management's 13F filing for Q2 2024, filed 13 Aug 2024.